Blockchain Registration Transaction Record

Helus Pharma's CMO to Speak at H.C. Wainwright Neuro Conference

Helus Pharma CMO Amir Inamdar to present at H.C. Wainwright Neuro Conference, discusses novel serotonergic agonists for depression and anxiety. Learn about HLP003 and HLP004.

This news matters because Helus Pharma is at the forefront of developing novel treatments for mental health conditions like depression and anxiety, which affect millions worldwide. The fireside chat at a prestigious conference signals growing investor and industry interest in their NSA pipeline, particularly HLP003 and HLP004, which could offer more effective and durable therapies. For patients and healthcare providers, successful development of these drugs could mean improved outcomes and new options for those who do not respond to existing treatments.